Physician

Aiman Nassrallah Daghestani, MD

According to 2025 Medicare claims, Aiman Daghestani, MD (NPI: 1336149897) practices medical oncology, with the plurality of this provider's patient population coming from Somerset, PA. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY ASSOCIATION INC (NPI: 1861469223; TIN: 251762980) and primary practice location at 15501-2033. Daghestani is affiliated with the Franciscan ACO, Inc. (ACO ID: A2550), Physician Partners of Western PA LLC (ACO ID: A3547), and AdvantagePoint Health Alliance - Laurel Highlands, LLC (ACO ID: A4657), participating under the MSSP model.

Daghestani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 339 traditional Medicare patients, billed 1,222 HCPCS/CPT codes, and received $99,149 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,353 prescription claims across 262 beneficiaries totaling $4,437,659 in drug costs, led by Xtandi (Enzalutamide). DME data shows 51 claims. Open Payments data shows 2 records totaling $91. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $597,068 to $99,149. In contrast, Part D prescription costs have moved sharply higher in recent years, from $642,267 to $4,437,659. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	197	53,366	$597,068
2016	194	63,222	$722,524
2017	185	54,660	$642,708
2018	209	60,806	$598,650
2019	271	80,356	$1,197,445
2020	156	5,262	$95,289
2021	105	258	$17,388
2022	293	771	$61,068
2023	292	1,219	$101,153
2024	339	1,222	$99,149

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	86	508	$642,267
2016	102	668	$1,392,316
2017	107	682	$1,401,930
2018	115	607	$1,442,336
2019	115	444	$1,493,338
2020	53	188	$590,586
2021	48	128	$252,284
2022	97	340	$439,732
2023	197	948	$2,577,884
2024	262	1,353	$4,437,659

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	36	$849
2017	N/R	12	$9,095
2018	N/R	54	$1,313
2019	N/R	26	$595
2020	N/R	48	$1,040
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	23	$12,330
2024	N/R	51	$1,560

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	59	370	$105
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	59	63	$101
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	50	50	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	219	540	$67
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	70	130	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	58	1,740	$813,826
Calquence	Acalabrutinib Maleate	41	1,230	$619,044
Brukinsa	Zanubrutinib	21	622	$303,972
Promacta	Eltrombopag Olamine	12	360	$251,424
Abiraterone Acetate	Abiraterone Acetate	104	3,028	$213,366

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	33	$1,334
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	18	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$91	SEAGEN INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aiman Nassrallah Daghestani, MD?

Tedicare shows public-source Medicare data for Aiman Nassrallah Daghestani, MD (NPI 1336149897), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aiman Nassrallah Daghestani, MD have ACO affiliation data?

Aiman Nassrallah Daghestani, MD is shown with ACO affiliation data for Franciscan ACO, Inc. (MSSP, ACO ID A2550), Physician Partners of Western PA LLC (MSSP, ACO ID A3547), and AdvantagePoint Health Alliance - Laurel Highlands, LLC (MSSP, ACO ID A4657).

What billing organization is linked to Aiman Nassrallah Daghestani, MD?

Aiman Nassrallah Daghestani, MD is linked to ONCOLOGY HEMATOLOGY ASSOCIATION INC (billing NPI 1861469223) in the available physician profile data.

Does Aiman Nassrallah Daghestani, MD have Open Payments data?

Aiman Nassrallah Daghestani, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.